Breaking News Instant updates and real-time market news.

ATXI

Avenue Therapeutics

$4.90

-0.15 (-2.97%)

08:20
12/19/18
12/19
08:20
12/19/18
08:20

Avenue Therapeutics doses first patient in Phase 3 trial of IV tramadol

Avenue Therapeutics announced that the first patient has been dosed in a pivotal Phase 3 clinical trial of IV tramadol for the management of moderate to moderately severe pain in patients following abdominoplasty surgery. The Phase 3, multicenter, randomized, double-blind, three-arm trial will evaluate the efficacy and safety of IV tramadol 50 mg versus placebo. Approximately 360 patients will be enrolled to IV tramadol 50 mg, placebo or morphine in a 3:3:2 ratio. The primary efficacy endpoint is the summed pain intensity difference over 24 hours compared to placebo.

ATXI Avenue Therapeutics
$4.90

-0.15 (-2.97%)

07/13/18
OPCO
07/13/18
INITIATION
Target $8
OPCO
Outperform
Avenue Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leland Gershell initiated Avenue Therapeutics with an Outperform rating and $8 price target, telling investors that Avenue is an "under-recognized story" whose fundamentals belie its sub-$50M market cap. He believes the stock is very attractive at current levels, despite the next significant milestone being about a year away, and recommends investors use this opportunity to build a position.
06/25/18
HCWC
06/25/18
INITIATION
Target $11
HCWC
Buy
Avenue Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce initiated Avenue Therapeutics with a Buy rating and $11 price target, stating that its lead candidate, IV Tramadol, would be highly differentiated as the only IV opioid in the U.S. with a DEA Schedule IV if approved.
05/21/18
HCWC
05/21/18
NO CHANGE
Target $11
HCWC
Buy
Fortress subsidiary met endpoint in Phase 3 trial, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis says Fortress Biotech (FBIO) subsidiary Avenue Therapeutics (ATXI) announced this morning that its pivotal Phase 3 trial of IV tramadol achieved the primary endpoint in patients with moderate to moderately severe postoperative pain following bunionectomy surgery as well as important secondary endpoints. IV tramadol has the potential to be the first Schedule IV opioid in the U.S., and could be an important addition to pain treatments, Pantginis tells investors in a research note. The analyst currently projects $175M in peak sales, which he believes could be conservative based on the drug's profile. He reiterates a Buy rating on Fortress Biotech with an $11 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.